163 related articles for article (PubMed ID: 15021775)
1. Hearing changes after diagnosis in neurofibromatosis type 2.
Masuda A; Fisher LM; Oppenheimer ML; Iqbal Z; Slattery WH;
Otol Neurotol; 2004 Mar; 25(2):150-4. PubMed ID: 15021775
[TBL] [Abstract][Full Text] [Related]
2. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
3. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
5. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
6. Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.
Bonne N-; Aboukais R; Baroncini M; Hochart A; Leblond P; Broly F; Dubrulle F; Lejeune JP; Vincent C
Childs Nerv Syst; 2016 Dec; 32(12):2403-2413. PubMed ID: 27704245
[TBL] [Abstract][Full Text] [Related]
7. Vestibular evoked myogenic potentials in neurofibromatosis 2.
Wang CP; Hsu WC; Young YH
Ann Otol Rhinol Laryngol; 2005 Jan; 114(1 Pt 1):69-73. PubMed ID: 15697166
[TBL] [Abstract][Full Text] [Related]
8. Progress of hearing loss in neurofibromatosis type 2: implications for future management.
Kontorinis G; Nichani J; Freeman SR; Rutherford SA; Mills S; King AT; Mawman D; Huson S; O'Driscoll M; Gareth Evans D; Lloyd SK
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3143-50. PubMed ID: 25294053
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.
Tysome JR; Macfarlane R; Durie-Gair J; Donnelly N; Mannion R; Knight R; Harris F; Vanat ZH; Tam YC; Burton K; Hensiek A; Raymond FL; Moffat DA; Axon PR
Otol Neurotol; 2012 Apr; 33(3):466-72. PubMed ID: 22334163
[TBL] [Abstract][Full Text] [Related]
10. Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
deTorres AT; Brewer CC; Zalewski CK; King KA; Walker R; Scott GC; Asthagiri AR; Chittiboina P; Kim HJ
Otol Neurotol; 2018 Mar; 39(3):357-364. PubMed ID: 29342057
[TBL] [Abstract][Full Text] [Related]
11. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.
Slattery WH; Fisher LM; Iqbal Z; Oppenhiemer M
Otol Neurotol; 2004 Sep; 25(5):811-7. PubMed ID: 15354016
[TBL] [Abstract][Full Text] [Related]
12. Atypical hearing loss in acoustic neuroma patients.
Selesnick SH; Jackler RK
Laryngoscope; 1993 Apr; 103(4 Pt 1):437-41. PubMed ID: 8459754
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of vestibular schwannomas in type 2 neurofibromatosis.
Kishore A; O'Reilly BF
Clin Otolaryngol Allied Sci; 2000 Dec; 25(6):561-5. PubMed ID: 11122300
[TBL] [Abstract][Full Text] [Related]
14. Middle fossa decompression for hearing preservation: a review of institutional results and indications.
Slattery WH; Hoa M; Bonne N; Friedman RA; Schwartz MS; Fisher LM; Brackmann DE
Otol Neurotol; 2011 Aug; 32(6):1017-24. PubMed ID: 21725256
[TBL] [Abstract][Full Text] [Related]
15. Hearing rehabilitation outcomes in cochlear implant recipients with vestibular schwannoma in observation or radiotherapy groups: A systematic review.
Borsetto D; Hammond-Kenny A; Tysome JR; Axon PR; Donnelly NP; Vijendren A; Phillips V; Bance ML
Cochlear Implants Int; 2020 Jan; 21(1):9-17. PubMed ID: 31496442
[No Abstract] [Full Text] [Related]
16. Audiovestibular Characteristics of Small Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
Holliday MA; Kim HJ; Zalewski CK; Wafa T; Dewan R; King KA; Brewer CC; Butman JA; Asthagiri AR
Otolaryngol Head Neck Surg; 2014 Jul; 151(1):117-24. PubMed ID: 24718755
[TBL] [Abstract][Full Text] [Related]
17. Significance of cochlear dose in the radiosurgical treatment of vestibular schwannoma: controversies and unanswered questions.
Jacob JT; Carlson ML; Schiefer TK; Pollock BE; Driscoll CL; Link MJ
Neurosurgery; 2014 May; 74(5):466-74; discussion 474. PubMed ID: 24476904
[TBL] [Abstract][Full Text] [Related]
18. Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.
Zhao F; Wang B; Yang Z; Zhou Q; Li P; Wang X; Zhang J; Zhang J; Liu P
J Neurooncol; 2018 Jun; 138(2):417-424. PubMed ID: 29492767
[TBL] [Abstract][Full Text] [Related]
19. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of cochlear implantation in patients with neurofibromatosis type 2.
North HJ; Mawman D; O'Driscoll M; Freeman SR; Rutherford SA; King AT; Hammerbeck-Ward C; Evans DG; Lloyd SK
Cochlear Implants Int; 2016 Jul; 17(4):172-177. PubMed ID: 27691934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
